Your latest cannabis business info from Europe

Your latest cannabis business info from Europe


European Pharmacopoeia introduces cannabis monographs

European Pharmacopoeia Commission introduces cannabis monographs

In the area of cannabis, the European Pharmacopoeia Commission (EPC) has recently made significant improvements. The EPC approved three new general chapters and 11 new monographs during its 176th session, which took place in June 2023. One monograph focuses on cannabis flowers and cannabidiol isolated from Cannabis Sativa plant.

These updates to the European Pharmacopoeia (Ph. Eur.) reflect the rising acceptance of cannabis and its potential medical use. The development is extremely important for the regulation and quality control of cannabis-based products because the EPC’s criteria are legally binding in its member states.

Expanding the monographs

Two important monographs on cannabis and the cannabidiol (CBD), which is derived from the plant, are among the newly adopted texts. The cannabis flower monograph (3028) offers thorough quality guidelines for the plant material itself. This addition intends to maintain the security and consistency of cannabis flowers used in diverse applications while also acknowledging the growing interest in cannabis as a therapeutic resource.

Additionally, the cannabidiol (3151) monograph establishes quality requirements for isolated CBD, a compound derived from the Cannabis sativa L. plant that has drawn significant interest for its potential therapeutic properties, including its use in managing pain, epilepsy, and anxiety disorders.The monograph provides clear guidelines for the production, characterization, and quality control of CBD, establishing a framework for its safe and reliable use in medicinal products.

What does cannabis monograph mean for the producers and patients?

The addition of these cannabis monographs shows EPC’s dedication to maintaining the highest standards of quality and safety in the pharmaceutical business. The EPC makes sure that patients and medical professionals can rely on consistent and standardised goods. Moreover they had necessity to establish exact requirements for the composition, purity, and identification of cannabis flower and CBD. These monographs offer a scientific standard to follow, assisting in the harmonisation of cannabis-related laws throughout Europe.

By offering a legal framework for the development of cannabis-based medications, the acceptance of these cannabis monographs promotes medical innovation. Pharmaceutical companies can confidently conduct research and clinical trials to investigate the therapeutic potential of cannabis and its components if there are defined quality standards in place. The EPC expands the options available to patients in need and promotes the development of novel therapeutic options.

Cannabis in European Pharmacopoeia – what’s in it for the market?

First of all, the German Pharmacopoeia’s future in terms of cannabis standards may change as a result of the European Pharmacopoeia’s inclusion of cannabis monographs. The addition of cannabis monographs in the European Pharmacopoeia offers an opportunity for integration across European countries. It’s possible that the German Pharmacopoeia will adopt the same criteria as the European Pharmacopoeia.

Additionally, a variety of factors and the opinions of stakeholders will determine Pharmacopoeias use. It is crucial to keep in mind that different stakeholders, such as regulatory organisations, manufacturers, and healthcare practitioners, may have different viewpoints and preferences. Depending on specific demands and legal restrictions, the future landscape may involve using both for example.

Most importantly, the EPC has an impact outside of Europe. Worldwide acceptance of its criteria as a scientific standard has opened the way for a harmonisation of pharmaceutical rules. The EPC’s introduction of cannabis monographs will occur as a result of wide medical use of cannabis across the globe. By increasing the consistency and security of cannabis-related products, this united effort will guarantee high-quality medications.


How vertical integration can develop in diverse Europe?

Medical cannabis in Portugal: filling the gap of Clever Leaves


Sustainability and growth in the hemp&cannabis industry: Synbiotic